Haichang Bio Hosts Expert Advisory Meeting on Metabolic Disease Pipeline of Oligonucleotide Therapeutics and Files IPO Prospectus

Jul 03, 2026 13:27 CST Updated 13:27

Haichang Biotech

Innovative Formulation Developer

Recently, Haichang Biotech held a clinical expert demonstration meeting on the research and development of oligonucleotide drugs for metabolic diseases, focusing on metabolic dysfunction-associated steatohepatitis (MASH) and cutting-edge strategies in areas such as fat reduction.

Professor Li Haiyan from Peking University Third Hospital, Researcher Li Jingya from the Shanghai Institute of Materia Medica, Professor Fan Jiangao from Shanghai Xinhua Hospital, and Mr. Li Chao, General Manager of Tianjin Youji Pharmaceutical, were invited to attend. They delivered specialized reports on topics including MASH R&D strategies, key considerations for simultaneous regulatory submissions in China and the US, challenges in preclinical and clinical trials, and the current landscape of clinical treatment. The company’s R&D, non-clinical, and clinical teams engaged in in-depth discussions with the attending experts regarding the existing data foundation of candidate drugs, translational medicine challenges, and overall development strategies. A systematic evaluation was conducted on key scientific issues related to regulatory filings. Based on a prudent analysis of the available data, the subsequent clinical development pathway and registration planning were further optimized.

The demonstration meeting yielded fruitful results, with the experts’ insights providing valuable strategic guidance for project advancement. Based on the consensus reached at the meeting, the company will focus on three key areas:

Strengthen the R&D foundation, accelerate the validation of non-clinical efficacy, toxicology, and biomarkers, and optimize early clinical trial designs to more precisely guide subsequent dose selection and patient stratification;
Accelerate the strategic layout of a differentiated product pipeline, actively explore new mechanisms and application scenarios, and continuously enhance the competitiveness of our technology platforms;
Strengthen international regulatory communication, leverage cutting-edge technologies to enrich non-clinical data, and enhance the scientific completeness of global submissions.

Meanwhile, combination therapy strategies are regarded as a key direction for overcoming the bottleneck of disease fibrosis. The company will maintain an open attitude and actively seek external collaborations to accelerate the realization of clinical value through collaborative innovation.

This meeting not only cleared critical obstacles for the clinical translation of metabolic disease pipeline projects but also strengthened the team’s confidence in addressing major clinical unmet needs in metabolic diseases through innovative technologies. Haichang Biotech will seize this opportunity to accelerate the advancement of its pipeline, striving to forge a globally competitive new path in the field of small nucleic acid-based metabolic therapies and delivering truly accessible transformative treatments to patients.